Genzyme, now a Cambridge-based unit of the French drug giant Sanofi SA, said that regulators have given it approval to market a multiple sclerosis drug in the European Union. The drug is called Lemtrada, and it is one that Genzyme has high hopes for. Genzyme has a heritage in developing drugs for rare diseases.